A Phase 1 interventional study of ER-100 in glaucoma and optic nerve conditions

Study Description

Safety study of an experimental gene therapy (ER-100) for people with glaucoma or vision loss from blocked blood flow to the optic nerve

Study Details

Registry ID:

NCT07290244

Conditions:

Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)

Phase:

Phase 1

Target Enrollment:

18 participants

Start Date:

March 2, 2026

Age Range:

40–85 years

Healthy Volunteers:

No

Study Locations (4 sites)

• Mass Eye and Ear
  Boston, MassachusettsUnited States, United States
• Columbia University Irving Medical Center/Edward S. Harkness Eye Institute
  New York, New YorkUnited States, United States
• Charleston Neuroscience Institute
  Charleston, South CarolinaUnited States, United States
• Global Research Management, Inc.
  Glendale, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →